Back to search
FDAFDA · Food and drugs·Recall number Z-1059-2022

VITEK 2 Systems and VITEK 2 with MYLA.

Published May 18, 2022 · Recall initiated: March 29, 2022

Summary

FDA records medical device Class II recall Z-1059-2022, published May 18, 2022 and initiated March 29, 2022. Recalling firm: bioMerieux, Inc.; Status: Ongoing; Reported quantity: 21,757 systems; Lot: VITEK 2 - Versions 8.01, 9.01, 9.02 (with or without 9MR2), 9.03 (with or without #9MR2). VITEK 2 with MYLA - Versions 4.8 and 4.9. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Software issue where results sent to the LIS via HL7 format for antibiotic screen tests and synergy tests do not include the user-corrected or AES-corrected interpretation. This can potentially lead to incorrect final screen/synergy test results at the LIS.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
bioMerieux, Inc.
Distributor
U.S. distribution of the FSCA to NC. OUS distribution of the FSCA to subsidiaries in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Egypt, Finland, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Russia, Serbia, Sweden, Singapore, South Africa, South Korea, Spain, Switzerland, Thailand, Turkey, and United Kingdom.
Lot
VITEK 2 - Versions 8.01, 9.01, 9.02 (with or without 9MR2), 9.03 (with or without #9MR2). VITEK 2 with MYLA - Versions 4.8 and 4.9.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was VITEK 2 Systems and VITEK 2 with MYLA. recalled?

Yes. FDA published recall Z-1059-2022 on May 18, 2022. Reported hazard: Software issue where results sent to the LIS via HL7 format for antibiotic screen tests and synergy tests do not include the user-corrected or AES-corrected interpretation. This can potentially lead to incorrect final screen/synergy test results at the LIS.

What should I do if I have this product?

Voluntary: Firm initiated · Letter